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IS THERE ANYTHING NEW?
Helicobacter pylori has been for many years a for-
gotten bacterium, since the first reports on this spiral
organism date from the XIXth century.1 As early as in
1906, an association between a spiral organism and gas-
tric carcinoma was suggested.2 Doenges reported in 1938
that on autopsy not less than 40% of human stomachs
were found to be invaded by spiral organisms.3 In 1940,
the therapeutic effect of bismuth in patients with peptic
ulcer disease in the presence of spiral bacteria in the
stomach was reported.4 Then, interest in the bacterium
decreased. In 1982, two Australian researchers, Marshall
and Warren, re-discovered the microbe5, and called it
first Campylobacter pylori, later Helicobacter pylori.
Today, the complete genome (1590 genes) of H. pylori
has been unmasked (6,197) and published on the internet
(http://www.tigr.org), probably paying the way for se-
quencing the genome of other organisms, including that
of humans within a few years.7
WHY IS HELICOBACTER PYLORI SO IMPORTANT?
There is unequivocal evidence that H. pylori can be
considered as a healthcare issue because of the mortal-
ity associated with the infection, due to the risk of ulcer
bleeding and gastric cancer. Infection with H. pylori
results in the development of gastritis in all infected hu-
mans, including children and adolescents.8 Worldwide,
peptic ulcer disease is a major cause of morbidity and
distal gastric adenocarcinoma, which is the second big-
gest cancer killer world-wide.9 However, the majority of
infested individuals will remain free of symptoms through-
out their lifetime; only a small minority will present with
peptic ulcer disease (life time risk 15%), and an even
smaller proportion will develop gastric neoplasms includ-
ing (mucosa-associated lymphoid tissue) lymphoma and
adenocarcinoma (lifetime risk 0.1%).10 There is now di-
rect evidence of a causal link between Helicobacter
pylori and gastric cancer in an animal model.196 Over-
all, H. pylori can be discovered in 92% of children with
duodenal ulcers and in 25% of children with gastric ul-
cers.11 H. pylori infection is contracted primarily in child-
hood, and infection from childhood appears to enhance
the risk for carcinogenesis.12
ABOUT THE BACTERIUM: VIRULENCE
The microaerophilic, gram-negative, urease-produc-
ing H. pylori fulfills each of Koch’s postulates.8 In its
normal living form it is a spiral-shaped bacterium, but
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the coccoid form can also cause lesions. The bacterium
colonizes the stomach of man and induces severe mu-
cosal inflammation and a local and systemic immune re-
sponse. The bacterium is capable of changing its mem-
brane potential at external pHs from 3.0 to 7.0 in order
to maintain a neutral internal pH.13 All H. pylori strains
are not created equal.14; and not all strains are associ-
ated with clinical symptoms.
Some virulence factors such as urease and flagella
are present in all strains and are necessary for patho-
genesis and colonization. Flagella and thus motility, are
needed for persistent gastric colonization.15 The gene
FlbA is needed for flagellar expression.16 Enzymes pro-
duced by H. pylori have mostly metabolic, antioxidant,
and toxic properties17; most of these are produced by all
isolates tested. Urease is required to establish infection,
and is located intra- and extra-cellularly.15 Urease is a
nickel-containing metallo-enzyme, comprising of two
structural subunits, UreA and UreB.18 Urease is prima-
rily a cytoplasmic enzyme19, and hydrolyses urea to bi-
carbonate and ammonia, resulting in a net increase in
the ambient pH. Ammonia is a nutrient for the bacteria,
and causes lesions to the gastric epithelium by many dif-
ferent mechanisms20, Surface urease helps protect
against acid exposure, but it is as yet unclear why it is
found on bacteria deep underneath gastric mucus where
the pH is thought to be neutral. Because there is no ob-
vious urease export machinery, it has been suggested
that some bacteria undergo autolysis, following which
released proteins, including active urease, are absorbed
onto the surface of remaining intact bacteria.19,21
Urease might function as an adhesin, although this
suggestion has also been contradicted.22 Urease stimu-
lates the release of a variety inflammatory cytokines in-
cluding interleukin-beta, interleukin-6, tumor necrosis fac-
tor-alfa, and chemokines such as interleukin-8.23 Although
the exact mechanism by which urease functions in the
pathogenesis of gastric disease remains unclear, it is likely
that urease is an important virulence factor.
H. pylori can produce different kinds of phospholi-
pases weakening the hydrophobicity of the gastric mu-
cous and mucosa. Phospholipase also generate ulcero-
genic substances.24 Many other enzymes, such as
mucinase, neuraminidase, fucosidase, alcohol dehydro-
genase, etc. have been reported.20
The vacuolating cytotoxin A (VacA) gene is present
in A strains, but is only expressed in 50% of H. pylori
isolates.25 The vacuolating activity of VacA is increased
by exposure to acidic pH values.26 The vacuoles are
formed by merging of late endosomes and the mecha-
nism causing this has been determined.27 The VacA gene
exhibits different allelic combinations. Strains with the
gene s1/m1 have the highest levels of cytotoxic activity;
colonize the stomach more densely and are correlated
with peptic ulcer, atrophic gastritis and gastric cancer;
s2/m2 strains have no toxic activity.20,28
Other virulence factors, such as “cytotoxic-associ-
ated gene A” (cagA)-encoded proteins are only found
in a proportion of the strains. This might explain why not
all strains are associated with clinical symptoms, although
both cagA and the s1 vacA allele are unreliable as single
markers in determing the risk of developing peptic ulcer
disease.29 The cagA protein is a cryptic 128 kDa
immunodominant antigen produced by H. pylori. CagA
is a marker for a larger cluster of genes (40 different
genes 20) carded on a pathogenicity island that exhibits
variability between strains. CagA+ strains produce in-
creased amounts of interleukin 8.30 Gastric atrophy,
duodenal ulceration, and gastric carcinoma are more
common in patients infected with cagA+ than with cagA-
strains.31 But, cancer of the distal stomach and cancer
of the gastroesophageal junction may be reduced in pa-
tients infected with cagA strains.195 CagA negative strains
are very rare in some Far East countries such as China
and Korea and frequent in others such as Hongkong,
and are reported to be not a marker of specific disease
in these regions.32 However, allelic variations in the cagA
protein are found in different parts of the world. In West-
ern countries, cagA positive strains are associated with
gastric atrophy and peptic ulcer disease.33 But, there
appears also to be no association between cagA and
clinical symptoms or ulcers in children.32,34 Other puta-
tive virulence determinants are being discovered, such
as the neutrophil-activating protein (napA) gene, a gene
“induced by contact with epithelium” (iceA1), etc.20
However, according to recent data, it is suggested that
there is no correlation between the degree of inflamma-
tion and the presence of the cag-pathogenicity island,
cytotoxin production, vacA alleles associated with cyto-
toxin expression in children.35
Auto-immunity and host mimicry by expression of
blood group antigens may be a relevant phenomenon.
Adhesion of H. pylori is nonspecific although preferen-
tial to epithelial cells and is enhanced at low pH, induc-
ing epithelial cell reorganization and causing deep invagi-
nation of the apical membrane, explaining resistance to
topical antibiotic treatment.36 One host receptor for ad-
hesion appears to be a blood group O antigen, possibly
explaining why ulcers are more common in people with
this blood group.37 The H. pylori lipopolysaccharide
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(LPS) or endotoxin is unusually biologically inert com-
pared with that from other bacteria. However, the mecha-
nisms by which H. pylori LPS stimulates cells appears
similar to that of other types of bacterial LPS.38 H. py-
lori LPS often contains Lewis x and Lewis y blood group
antigens that are identical to those occurring in the gas-
tric mucosa.39 H. pylori presents bacterial epitopes to
the host which are similar to the structure on host gas-
tric epithelium; therefore, the host reacts with an auto-
antibody response recognizing gastric mucosa inducing
atrophic gastritis.40 Patients with a large parietal cell mass
and high acid secretion will have a predominantly antral
gastritis, predisposing to duodenal ulcer. People with a
small parietal mass and low acid output (or people on
proton pomp inhibitors) will be more prone to develop
atrophic gastritis and gastric malignancy.41 The variabil-
ity in occurrence of gastric cancer in different parts of
the world may only be partly explained by the preva-
lence of H. pylori. Apoptosis of gastric epithelial cells is
increased in H. pylori infection, stimulating crypt cell
proliferation, increasing the risk for mutagenesis.42 Atro-
phic gastritis enhances the development of intestinal
metaplasia, and is related to the intestinal type of gastric
carcinoma but not to diffuse gastric carcinoma.43 Intes-
tinal metaplasia is related to atrophic gastritis, which is
on its turn related to H. pylori infection.
SYMPTOMS
H. pylori infection in children is mostly asymptom-
atic and not associated with specific gastrointestinal
symptoms.44 H. pylori gastritis, in the absence of duode-
nal ulcer, does not appear to be associated with specific
symptoms.11,45-49 After eradication of H. pylori infec-
tion, symptoms are improved only in those children with
duodenal disease.46 Children with H. pylori gastritis
cannot be distinguished from non-infected children on
the basis of initial symptoms.45,49 Many studies failed to
demonstrate a difference in H. pylori infection rate in
children with or without recurrent abdominal pain,11,49-51
although others did find this association. Recurrent ab-
dominal pain would occur during the acute phase of H.
pylori infection.52 It is unclear whether children with
recurrent abdominal pain with H. pylori represent a dif-
ferent entity to those without H. pylori. H. pylori posi-
tive children might more often have pain related to meals
than H. pylori M negative children. Ulcer-like symp-
toms maybe more closely associated with the infection
than other symptom-complexes.53 Talley et al. Provided
recently substantial evidence that (at least in adults)
Nonulcer dyspepsia is not related to H. pylori infec-
tion, since 46% of H. pylori eradicated en 50% of non-
eradicated patients did no longer complain of nonuleer
dyspepsia after one year follow-up.188 In adults, a sig-
nificantly lower H. pylori prevalence is reported in pa-
tients with gastro-esophageal reflux disease.54 The role
of H. pylori in duodenogastric reflux is unclear. A de-
creased mean acid output in subjects with H. pylori
gastritis might explain the inverse relation between re-
flux and H. pylori. Heartburn and epigastric pain might
be more frequent in H. pylori infected patients. Pooled
data from 18 studies suggest that the prevalence of H.
pylori is greater in patients with dyspepsia than in con-
trols.53 It is unclear whether H. pylori changes gastric
emptying rate or not, although most data suggest gastric
emptying is normal.55-57 In adults, H. pylori is also be-
yond any doubt associated with an increased incidence
of gastro-intestinal cancer. However, the high prevalence
of early H. pylori infection and chronic gastritis in chil-
dren contrasts with the rarity of gastric cancer in black
Africa.58 Nevertheless, acquisition in (early) childhood
is in general considered to be significant risk factor to
develop gastric carcinoma48, although gastric cancer is
rare in regions with a high infection rate (e.g. Africa).
Similarly to other chronic inflammatory conditions, in-
fection with H. pylori has been linked to reduced
growth59-65, although socioeconomic factors confuse the
issue. Tunior necrosis factor-alpha is inversely corre-
lated with growth, and is increased in I-I. pylori.66 How-
ever, studies have also failed to find differences in he-
moglobin, leukoeytes, thrombecytes, weight and
height.50,67 Differences in growth seem to be limited to
developing countries.62,63 It has been speculated that H.
pylori acquired in infancy could be “key that opens the
door” to enteric infection leading to recurrent diarrhea,
malnutrition and growth failure.62 There is, however, no
difference in diarrhea prevalence in relation to H. py-
lori status.68 After control for socioeconomic status, there
is no difference in the height of adults with and without
H. pylori. H. pylori seropositivity is related to a late
menarche.69,70 Socioeconomic status and malnutrition
does not explain late menarche, since elevated body mass
index is also independently associated with H. pylori in
the same population.70 Incidentally, anemia, hemoptysis
and vertigo have been reported.71,72 The association of
H. pylori with extra-digestive diseases, such as func-
tional vascular diseases and skin and endocrine autoim-
mune diseases, has been described.73-76 An interesting
relationship between seropositivity to H. pylori, serum
glucose and non-insulin dependent diabetes mellitus is
worthy of further attention. Recent studies suggest that
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the association between H. pylori and coronary heart
disease is rather weak,65,73 although again sugested in a
recent study.198 Primary Raynaud’s phenomenon, ob-
served in young women, which is defined by an intermit-
tent vasospasni of the arterioles of the distal limbs that
occurs mostly following exposure to cold or emotional
stimuli, may be related to H. pylori in some cases. H.
pylori may in addition cause headache.74 Vasoactive
substances, such as cytokines (interleukins, interferon,
gamma, TNF-alpha), prostaglandins, leukotrienes,
oxyradicals, C-reactive protein and fibrinogen are re-
leased in chronic infection,74 Henoch-SchÖnlein purpura
and SjÖgren’s syndrome have been correlated with the
bacterium. Many patients with auto-immune thyroid dis-
eases are infected with type-i-eytotoxic cagA-positive
strains.75 Rosacea and recurrent urticaria may also be
associated with H. pylori infection.76 Alopecia areata is
associated to atrophic gastritis and pernicious anemia,
and thus with H. pylori.74 Until now, H. pylori has not
yet been reported to cause hepatitis in human. Although
a mice Helicobacter species has been reported to cause
hepatitis in germflee mice, and H. pylori has been iden-
tified in the gallbladders of human.77,78 An Italian group
showed a positive correlation between food allergy and
H. pylori.79
HELICOBACTER PYLORI IN INFANTS AND CHILDREN
According to the Canadian consensus, indiscriminate
testing in children is not recommended.192 Independent
risk factors for H. pylori infection in infants and chil-
dren include living in developing countries, lower socio-
economic circumstances, living in overcrowded circum-
stances and sharing a bed with a parent. Human
lactoferrin can support H. pylori growth in vitro and H.
pylori binding lactoferrin has now been identified. In-
fants born to seropositive mothers passively acquire
maternal H. pylori lgO.80,81 Transplacentally transferred
maternal anti-H pylori IgG lasts until about the third month
of life in most infants and disappears from nearly all by 6
months.80 lgA in mother’s milk protects the infant from
H. pylori infection.82 However, whether breast feeding
is associated with a low or high prevalence of H pylori
infection in infants is still unclear80,83,84 (protective ef-
fect of mother’s milk versus intimate contact between
infant and H. pylori positive mother). At the age of 14
months, 7.5% of infants in a population with a
seroprevalence in young adults of 62%, had acquired H.
pylori, an event demonstrated by a raise in IgM, quickly
disappearing and preceding IgG.80,85,86 In an industrial-
ized country (Belgium), less than 1% of infants are se-
ropositive at the age of 1 year87(seropositivity in young
adults: about 30%).87,88 In Finland, 4% of all children
under the age of 7 year have a positive serology.89 Ap-
proximately 30% of 53 children (16/53) with dyspepsia
were infested with H. pylori in the antrum, and about
half of theni a cytotoxic train was present (anti-Cag A
antibodies in 64% and anti-vacA antibodies in 43%). In
only 6/53 children, the H. pylori was also detected in
the gastric body.90 Clinical evaluation showed a signifi-
cant difference in favor of subjects positive for H. py-
lori only for epigastric burning and/or pain.90 Clinical
symptoms associated with H. pylori infection have been
reported in patients with human inuninodeficiency virus
(HlV)-1.91,92 Although H. pylori has been said to be
rare in HIV-1 infected individuals (e.g. because of the
repetitive and multiple administrations of antibiotics and
immunoglobulins),92 recent data suggest that the preva-
lence of H. pylori infection in HIV-1 infected children
is comparable to the prevalence in the non-infected con-
trol population.91
DIAGNOSTIC AND SCREENING TOOLS
A large number of invasive and non-invasive meth-
ods have been used to diagnose H. pylori infection in
humans.93 Culture of the organism is best standard
method for the diagnosis of any bacterial infection. H.
pylori can be cultured from gastric biopsies. Culture of
H. pylori requires a microaerobic atmosphere of 5%
oxygen with 5-10% C02. When H. pylori is cultivated
on biopsy, sensitivity to antibiotics should be tested,94
whether coccoidal forms also grow in blood agar or not
is controversial.95,96
Histologic examination of Giemsa or Warthin-Starry
stained gastric biopsy specimens is widely used for the
diagnosis. The Sydney criteria for the classification of
gastritis have been revised.97 Gastric biopsy urease tests
make use of a change in color of phenol red which is
present in the medium because of a pH increase related
to the digestion of urea by the urease. Four rapid urease
tests are available commercially: CLO-test (Delta West
Ltd, Bentley, Austraha), Hpfast (GI Supply, Philadelphia,
USA) and PyloriTek (Serin Research Corporation,
Eikhart, USA), Jatrox (Rbhm Pharma GMBH,
Weiterstadt, Gerinany), although many hospitals prepare
their own urease tests. These commercial tests have a
high specificity and sensitivity and provide comparable
results.98 PyloriTek has a shorter reading time than CLO-
test.99 Antral and corpus biopsies provide comparable
results, and in combination they increase the sensitivity
by 4.3%.100 Although these biopsy urease tests have a
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high degree of sensitivity in adults, false negative results
are common in children, possibly because of a smaller
bacterial load.101
Molecular methods for biopsy material or other bio-
logical samples and current PCR methods for molecular
fingerprinting of H. pylori have been developed.102,103
PCR techniques can quantitate the bacterial load in gas-
tric samples.103,104 Several molecular methods have been
applied to typing H. pylori isolates, demonstrating their
genomic diversity. Unfortunately, all these tests necessi-
tate endoscopy.103
Magnetic beads coated with anti-H. pylori rabbit an-
tibodies permit detection of less than 10-million organ-
isms per gram of feces.105 PCR-delection of H. pylori
in feces is hindered by the presence of inhibitors of Taq
polymerase, complex polysaccharides which can be elimi-
nated by filtration on Qiagen and dilution. But,
immunomagnetic separation-PCR is recently reported
to be simple, rapid and reliable.106 Recently, PÜspÖk and
colleagues reported a sensitivity of 90% and specificity
of 92% of detection of H. pylori in stool specimens of
72 consecutive (adult) patients using the PREMIER H.
pylori Stool Antigen Test,187 suggesting that this non-
invasive method is very promising for the detection of
H. pylori.
The ability to detect antibodies in saliva rather than in
serum would improve antibody tests by avoiding the need
for blood collection.107 Sensitivity (84-93%) and speci-
ficity (70-82%) are too low, but comparable to rapid whole
blood diagnostic tests.107-109 The discovery of the poten-
tial importance of the caga-pathogenicity island has stimu-
lated interest in the specific detection of the CagA pro-
tein.
Serologic testing for IgG antibodies against H. py-
lori requires validation of the assay in children, since
antibody levels differ in children and adults, probably be-
cause of the duration of infection and the differences in
bacterial load.85, 106,110,111 In addition, commercially avail-
able serologic tests demonstrate lower accuracy com-
pared with testing in a research setting,112 with some-
times up 33% false positive and 25% false negative re-
sults.111,113,114 Serology is more and more frequently re-
ported to be unsatisfactory for screening and for diag-
nosis of H. pylori infectionin children.106,111,192,193 Test-
ing should not rely on office tests.94 After eradication,
there is a slow decline in antibody titer. Many patients
remain seropositive 1 year after eradication.115 At ac-
quisition of the infection, there is a temporary rise in
IgM.80,85,86,111,116 lgA is also reported to be a useful se-
rologic screening tool.117 Immunoblot has become the
reference method used to confirm doubtful results.118
Specific serologies for cytoxic strains may appear to be
helpful in selecting patients for treatment.90
Carbon-13 and C-14 breath tests are based on the
fact that urease from H. pylori will hydrolyze the in-
gested labeled urea into ammonia and labeled bicarbon-
ate, which is exhaled as labeled carbon dioxide.18
Whether a test meal should be given, or whether the
labeled urea should simply be given after a period of
fasting, or whether addition of citric acid would be ben-
eficial is not clear.119-121 A standardized and simplified
C-13 breath test was recently described in children.122
The high sensitivity and specificity of the 13C-breath
test in the detection of H pylori infection in children has
been unequivocally demonstrated.90,123,124 The best cut-
off value is obtained after 30 minutes.120 False positive
results can occur because of the presence of other ure-
ase containing gastric bacteria or because of extra-gas-
tric bacterial urea metabolism (seldom). False negative
results are mainly due to fast gastric emptying or previ-
ously administered urease-inhibiting drugs, such as anti-
biotics or bismuth-containing salts. There is a close cor-
relation between the urea breath test and the intragastric
bacterial load,100,125 which is on its turn related to the
severity of the gastritis. Unfortunately, carbon-13 breath
tests are still expensive in many parts of the world. A
less expensive method for the analysis of 13C-labeled
carbon dioxide is nondispensersive infrared spectrom-
etry, with a comparable sensitivity and specificity.126 But,
infrared spectrometry necessitates larger volumes of ex-
pired air, making the technique less suitable for (small)
children. Alternatively, measurement of 14C-labeled car-
bon dioxide with a scintillation counter is relatively inex-
pensive.127 Although the dose required for one test is
not greater than the natural background radiation, the
use of 14C is considered unethical in pregnant women,
adolescents and children because of its extremely long
half-life, since 14C may be incorporated into the bicar-
bonate pool.128 The urea breath test is in general ac-
cepted to be the most reliable noninvasive diagnostic
method.90,129 The urea breath test detects only current
infection and be used to screen for H. pylori infection
and as the sole method for assessing eradication, and to
evaluate treatment efficacy.129
EPIDEMIOLOGY
The prevalence of H. pylori infection in many popu-
lations and/or subgroups is currently well documented.
The overall prevalence of H. pylori in children is 10%
in developed countries but can be as high as 30-40% in
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children from lower socioeconomic classes. In develop-
ing countries, the prevalence of H. pylori in children
ranges from 80 to 100%.48 Like many other childhood
bacterial infections, H. pylori is most frequently acquired
in the preschool age group, with the associated effects
of family size, clustering in families, low socioeconomic
status and education and variable risks associated with
gender.89,130,131 Recent sociocultural changes may re-
sult in changes in infection rates in children,132 which is
an important argument for the cohort effect. In general,
it is thought that spontaneous eradication of H. pylori
infection is extremely rare.133,134 However, recently some
authors have suggested that from 1.5 up to 10 or even
20% of spontaneous eradication occurs in a period of 6
month during childhood.111,135,136,189 Although, others still
report a zero incidence of seroreversion.89 These dis-
crepancies may, however, be related to the methodology
(serology versus urea breath test). Recent epidemiologic
data suggest that serology underestimates H. pylori in-
fection in children,106,111 and antibodies may persist al-
though H. pylori disappeared.
In the developed world, acquisition by adults and chil-
dren is approximately 1 to 3% per decade,131,136,137which
will result in a dramatic decrease in H. pylori infection
in that part of the world in the coming decades. In the
Netherlands, about 40% of the 60-69 years old popula-
tion is seropositive137; since the prevalence in adoles-
cents is below 10%138, it can be speculated that the se-
ropositivity of this cohort will probably not be higher than
25% when reaching the age of 70 years. In Gambia, the
prevalence of a positive breath test at the age of 3 months
is about 19%, increasing to 84% at 30 months.111
Re-infection probably does not occur frequently and
is, in many cases, considered recrudescence after treat-
ment failure.139 Re-infection rates vary strongly with the
effectiveness of the treatment protocol.139,140 In Chile,
re-infection occurred in 4.2% after 1 year, with a treat-
ment protocol that was 82% effective.141,142 Annual user-
relapse rate in children with duodenal ulcer in whom H.
pylori was eradicated was reported to be 9%.143 The
percentage of re-infection does not appear to be much
greater in developing countries than in developed regions.
As a consequence, there is little reason for treating an
entire family to prevent re-infection, although spread from
one adult to another has been suggested.144 Others do
suggest family treatment.183 It seems more likely that
reinfection occurs from an external source. Of course,
a more detailed specification of the H. pylori strain will
contribute to the answer whether re-infection rather than
relapse occurs. Repetitive extragenctic palindromic-PCR
can group isolates into clusters that appear to have a
different clinical expression.102 Oligonucleotide probes
containing short repetitive sequence motifs can differ-
entiate between different isolates of H. pylori.146
The major mode(s) of transmission of H. pylori are
still unknown: oral-oral, gastro-oral and fecal-oral have
been proposed.147,148 Infected parents, especially moth-
ers, may have a key-role in transmission of H.pylori
within families. 81,149 Houseflies could serve as vectors
for H. pylori.150 Pets have been suggested as well as
contradicted to be vectors.151 There is considerable evi-
dence of transmission of oral bacteria between spouses
and between family members.144 Vomiting and gastro-
esophageal reflux might also be a mode of oral-oral con-
tamination.152 Mode of spread remains an active area of
study, with water as a source of contamination still of
potential interest. The coccoid form can cause cellular
changes similar to the spiral form,153 and may serve as
the infectious form in environmental sources such as
water154 Studies on external water sources in Peru re-
vealed PCR products of H. pylori in the municipal wa-
ter, increasing 12-times the risk for infection.155 The ex-
amples of studies in Peru and Chile suggest a role for
water as a vehicle, but it does not seem to be the main
route of acquisition since many studies in Korea132, Tai-
wan, or Turkey do not support this hypothesis.
HOST RESPONSE TO H.PYLORI
Another factor contributing to the heterogenceity of
H. pylori-associated symptoms is the variability in host
response to the infection. Duodenal bicarbonate secre-
tion is decreased in ulcer patients, and returns to normal
after eradication of H. pylori.156,157 Acute H. pylori
infection has been associated with hypochlorhydria, pos-
sibly by stimulating the production of a histamine-3 re-
ceptor agonist, which inhibits gastric acid output, In con-
tradiction to this finding is the observation that the same
histamine-3 receptor agonist can stimulate parietal cells
to produce acid via the histamine-2 receptor.158 Identifi-
cation of Lewis carbohydrate structures on H. pylori
lipopolysaccharide may provide an explanation for the
development of autoantibodies, reacting with gastric
mucosa (“molecular nmicry”).159
TREATMENT
Currently, there are no guidelines on the need to treat
children48 The regimens that have been studied to date
have used bismuth preparations, H2-receptor antagonists,
ranitidine bismuth citrate, proton pump inhibitors and
Y. Vandenplas, B. Hegar: Helicobacter pylori infection in children
Volume 1, Number 1, December, 2000 19
various antibiotics. The goal of any treatment should be
to achieve an eradication rate of over 80% on a rigorous
intention-to-treat basis.94 The Canadian and most Euro-
pean H. pylori study groups now recommend (in adults)
a triple regimen: a twice daily dose of proton pump in-
hibitor (PPI) in combination with two antibiotics (from
the following 3 groups : clarithromycin, amoxicillin;
nitroimidazoles (metronidazole or tinidazole)) for 1
week.94,160,161, 190,191,194 Talley et al. achieved a 90% eradi-
cation in adults with day administration of 40 mg
omeprazole, 2000 mg amoxicillin and 1000 mg of
chlarithromycin during 2 weeks.188
There are no specific recommendations for children
yet.162 It has been hypothesized that combination therapy
is more effective because of the synergistic mechanisms
between different drugs. The requirement is for a simple,
well tolerated regimen, with which it is easy to comply,
and is cost-effective. In a recent Irish study in children,
the therapeutic approach consisted of colloidal bismuth
subcitrate (480 mg/1.73 m2 body surface, 4 weeks) in
combination with amoxicillin (750 mg/day, 2 weeks) or
metronidazole (20 mg/kg/day, 2 weeks).120 In most Eu-
ropean countries, eradication treatment in children con-
sists usually of a PPI in combination with amoxicillin and
either clarithromycin or nitroimidazole, based on the sen-
sitivity of the prevailing strains. Although antibiograms
are needed, there seems to be major discrepancy be-
tween in vitro testing and in vivo efficacy. Resistance to
amoxicillin has recently been reported, but seems rare.163
Resistance to macrolides is rising with increasing use of
the drugs, and for both macrolides and nitroimidazoles.
There is a huge regional variation in resistance patterns.
Especially determination of resistance to metronidazole
may be relevant in regions with a high percentage of
resistance.164
Bismuth triple therapy continues to achieve high eradi-
cation rates worldwide (78-89%). Side effects leading
to diminished patient compliance and the marked decline
of eradication efficacy in cases of metronidazole resis-
tance are considered to be the major drawbacks of this
therapy. PPI dual therapy is better tolerated with fewer
side effects than is bismuth triple therapy. The mean
eradication rates vary from 55 to 75%, and the extremes
lie between 24 and 93%. PPI triple therapies have been
shown to be very effective against H. pylori (eradica-
tion rate 80-90%). Eradication rate in children with 2
weeks of treatment with clarithromycin, amoxicillin and
proton pump inhibitors (omeprazole or lansoprazole) is
reported to be 75 and 92%, respectively.165,166
Omeprazole, clarithromycin and metronidazole or
tinidazole for 7 days are reported to cause eradication in
87 and 89%.167,168 Dual therapy for 2 weeks with
omeprazole and amoxicillin causes eradication in 70%
of infected children, whereas addition of clarithromycin
(2 weeks) increases the eradication rate up to 92%.169
Amoxicillin, bismuth and metronidazole were reported
to eradicated H. pylori in 96% of infected children.143
Quadruple therapy leads to a mean eradication rate of
96%. Thus, based on efficacy PPI triple or bismuth triple
therapy are recommended as first-line treatment.170 The
cost of PPI versus bismuth should be considered. How-
ever, compliance strongly influence the eradication rate,
and may explain why, in contradiction to experience in
adults, in chddren two drugs (2 weeks) are sometimes
found to be equally effective than triple therapy (1
week).171
Eradication therapy is not recommended for all H.
pylori infected adults and children.162 However, the com-
plex relationship between H. pylori and gastro-intesti-
nal cancer might stimulate the physician to prescribe eradi-
cation treatment, even in the absence of scientific evi-
dence, especially in countries with a strong impact of
legislation on health care, as in the case in the US. In
children, not one randomized prospective placebo-con-
trolled study had been conducted. Whether children with
symptomatic H. pylori gastritis alone will benefit from
treatment is debated.90,121 Well designed clinical trials
showing a therapeutic gain of H. pylori treatment over
placebo are still missing, with the exception in duodenal
ulcer patients. The cost-benefit ratio of avoiding endos-
copy in dyspeptic patients is only worthwhile consider-
ing if the cost of endoscopy is greater than 500 US$172,
as is the case in the US; while the cost of upper gastro-
intestinal tract endoscopy in Belgium and Finland is only
about 100 and 170 US$, respectively.173
Nevertheless recommendations in Europe and the
USA differ. The European consensus states that scien-
tific evidence for the improvement of functional dyspep-
sia is equivocal, but the overall evaluation taking into
account the expected benefit on the gastritis status makes
it nevertheless worthwhile to consider eradication therapy
in such a patient. In Europe, it is accepted (although not
unanimously) that young patients, aged below 45 years,
without alarm symptoms (anemia, weight loss, dys-
phagia, palpable mass, malabsorption, etc.) and who test
positive for H. pylori for the first time (with validated
serology or breath test), can be treated with eradication
therapy without further investigation (thus, without en-
doscopy)94,160 However, in the USA, the present con-
sensus states that there is no scientific evidence to rec-
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ommend treatment for H. pylori in the absence of an
established peptic ulcer disease.156 As a consequence,
according to the North-American consensus, non-inva-
sive testing cannot replace endoscopy in the initial diag-
nosis of H. pylori related gastrointestinal diseases (also
not in children).174
Eradication of H. pylori in patients who do not ben-
efit from it may unnecessarily increase the risk of resis-
tance of H. pylori to antibiotics. But, it was shown in
pediatric patients that despite stable H. pylori coloniza-
tion and in the absence of symptoms, there was a dete-
rioration in the histologic features of the gastric mu-
cosa.189
H. pylori and non-steroid anti-inflammatory drugs
(NSAIDS) are both ulcerogens; however, NSAIDs are
not frequently prescribed in children, and, moreover, there
seems to be no cooperative effect between them. As a
consequence, eradication of H. pylori prior to NSAID
administration is not recommended in the USA. In Eu-
rope, eradication of H. pylori before NSAIDs is con-
sidered “advisable”.
Elimination of H. pylori increases the risk of devel-
oping gastro-esophageal reflux and reflux esophagi-
tis.157,175 H. pylori eradication results in a marked de-
crease in the pH-increasing effect of omeprazole and
ranitidine.176 Nevertheless, long term acid suppressive
therapy with proton pump inhibitors (and to a lesser ex-
tent with H2-antagonists) for reflux disease in H. pylori
positive patients enhances the development of atrophic
gastritis, if H. pylori has not been eradicated before-
hand.177,178
Eradication of H. pylori can be demonstrated by nor-
malization of histology and negative culture of gastric
biopsies, or with the use of urea breath tests.94 With re-
spect to serology; a 50% fall in antibody titers is indica-
tive of successful elimination. However, this usually re-
quires up to 6 months to occur.179 When follow-up tests
for eradication of H. pylori are necessary, they should
not be performed earlier than 4 weeks after cessation of
treatment.94 The bacterial load could influence the suc-
cess rate of eradicating treatment.180
Knowledge of the H. pylori genome provides major
new insights into many aspects. Conversion of pyruvate
to acetyl-CoA uses an unusual enzyme, only previously
found in free-living bacteria from extreme environ-
ments181 and the genome sequence shows that acetyl-
CoA is likely to be a crucial intermediary in several bio-
synthetic pathways. Therefore, blocking the enzyme
should allow effective and selective drug activity against
H. pylori. The same is true for many other enzymes.
VACCINATION
Study of the H. pylori outer membrane is important
both for understanding pathogenicity but also for devel-
opment of vaccines since the outer membrane is involved
in adherence to the host epithelium and stimulation of
the host immune response. Vaccines should be able to
confer preventive and curative immunity on humans. Oral
immunization with a recombinant urease given in the ab-
sence of a mucosal adjuvant has been assessed unsuc-
cessfully in H. pylori-infected volunteers182 (urease is a
cytoplasmic enzyme). However, recently, the recombi-
nant H. pylori urease was given with an Escherichia
coli heat-lable toxin, provoking diarrhea in the majority
of the volunteers (a side-effect which disappeared when
the dose was reduced), but also showing an increase in
urease specific lgA-producing cells and a decrease in
the density of gastric colonization by H. pylori.183
lgA antibodies are expected to play a prominent role
in protection, since H. pylori is a non-invasive pathogen
at the luminal surface of the gastric mucosa. This hy-
pothesis has been supported by the observation that milk
lgA protects infants against H. pylori infection.82 lgA
and immunoglobulin 01 (IGGI) depend on T-helper type
2 (Th2) cells. According to different recent experiments,
immunization is associated with an elevation of IgG 1
levels, indicative of a Th2 cellular immune response, which
might he a significant mechanism.184-186 The field of vac-
cination is still very controversial and is being extensively
studied.
CONCLUSION
Helicobacter pylori infection is worldwide one of
the most frequent infectious diseases. There is a huge
discrepancy in prevalence and incidence between the
Western industrialized countries and the rest of the world
(Africa, Asia, South-America). Infection occurs mainly
in children. Well designed studies to identify those in-
fected children who are at risk of developing complica-
tions or have symptoms due to the infection are still lack-
ing.171 Because of the cohort-effect which is related to
the socio-economic status and/or hygienic circumstances,
the annual infection rate in the Western world is dra-
matically decreasing. If this observation is confirmed, it
can be speculated that a decrease in incidence of peptic
ulcer disease and gastric cancer may occur in the indus-
trialized world during the next decades. (However,
duodenal ulcer and gastric cancer are only related to
some -more virulent- strains). Many children remain
asymptomatic, and a clear relation between H. pylori
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and symptoms has only been demonstrated for ulcer-
related symptoms. In addition, peptic ulcers are rare in
childhood. Treatment of H. pylori is indicated in (duode-
nal) ulcer disease. The relation between chronic abdomi-
nal pain (and functional dyspepsia) and H. pylori is un-
clear.
Screening tests, including serology or the urea breath
test, are of interest for epidemiological studies. The urea
breath test evaluates the actual colonization; scrum anti-
bodies might persist after eradication, which is only rarely
spontaneous. According to the European consensus,
eradication therapy can be considered in a child with
functional dyspepsia and positive screening test. Accord-
ing to the North American consensus, treatment is only
recommended in the presence of ulcer, necessitating
endoscopy.
H. pylori strains are not created equal since impor-
tant virulence factors are not detectable in all strains.
The continuous decline of H. pylori prevalence as a
result of changes in living conditions and active treat-
ment is not unanimously considered to be beneficial.14
Unfortunately, screening tests rely on virulence factors
which are detectable in all strains: the presence of ure-
ase, or the immune response of the host by measuring
lgG antibodies. Vaccines will not become available in
the near future. Nevertheless, in all countries, improve-
ment of the socioeconomic status and hygienic circum-
stances will result in a dramatic decrease of H. pylori.
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